Crohn's Disease News and Research

Latest Crohn's Disease News and Research

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced positive results from an open-label pilot study of XOMA 052 in patients with uveitis of Behcet's disease who were suffering from vision-threatening exacerbations despite maximal doses of immunosuppressive medicines.

17 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Disease is a private matter to many of us. For many reasons, we want to keep it to ourselves, and no cluster of disorders challenges patients' need for privacy more than inflammatory bowel disease.

10 Jun 2010

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.

10 Jun 2010

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Chelsea Therapeutics International, Ltd. announced that during a teleconference yesterday, the U.S. Food and Drug Administration requested that the company delay the initiation of its proposed Phase II clinical study of CH-4051 in rheumatoid arthritis and indicated that the agency is requesting additional detail from the preclinical studies previously submitted as part of the company's investigational new drug application.

9 Jun 2010

Boosting levels of ABCG1 protein in diabetics will improve insulin production

If you think of diabetes onset like an elaborate molecular drama, then a research team led by a La Jolla Institute scientist has unmasked a previously unknown cellular player, which is critical to proper insulin secretion. "Defective insulin secretion is a hallmark of both type 1 and type 2 diabetes," said Catherine Hedrick, Ph.D., a scientist at the La Jolla Institute for Allergy & Immunology, who led the team, which included researchers from the University of Virginia.

8 Jun 2010

$Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer$

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in women with platinum-resistant/refractory ovarian cancer. A total of 68 patients were enrolled with platinum-resistant disease, half of whom were platinum refractory. All 68 patients were evaluable for the primary endpoint of objective response rate using Gynecologic Cancer InterGroup criteria, which is a combination of response by tumor imaging (RECIST) and/or ovarian cancer biomarker (CA-125) criteria.

8 Jun 2010

La Jolla Institute scientist finds protein key to insulin secretion

8 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

ACG announces release of new IBD podcast series

The American College of Gastroenterology announced the release of a new podcast series, "Audio Q&A on Inflammatory Bowel Disease," featuring ACG experts answering questions on topics of most concern to IBD patients, their caregivers and loved ones. In recognition of World Digestive Health Day—2010 the Year of IBD, the College's new podcasts emphasize helping patients live well despite their IBD, and address issues surrounding reproduction and fertility; diet and nutrition; new and emerging therapies; the importance of clinical trials; and pediatric IBD.

28 May 2010

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Nektar Therapeutics today announced that results from the Phase 2 clinical trial of NKTR-102 in women with platinum-resistant/refractory ovarian cancer will be presented at the Oral Abstract Session of the Gynecologic Cancer Track during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO).

21 May 2010

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

Angiogenesis plays a crucial role in neoplastic and non-neoplastic chronic inflammatory disorders, including inflammatory bowel diseases (IBD). Several reports have shown that blockade of angiogenesis in preclinical models of IBD is a promising new therapeutic approach. Visualize angiogenesis in vivo may represent the first step for such a therapeutic approach. Narrow-band imaging (NBI) is a new endoscopic technology that highlights mucosal surface structures and microcapillaries.

21 May 2010

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the United States Patent Office (USPTO) has issued a patent (US 7,704,985) entitled "Treatment of Irritable Bowel Syndrome and Related Bowel Diseases." The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.

19 May 2010

SQI announces poster presentations on novel diagnostic assays at 7th International Congress on Autoimmunity

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based biomarker testing, today announced data from oral and poster presentations that highlights the Company's leadership position in the autoimmune diagnostics space.

14 May 2010

Prometheus announces novel method for early detection of HACA during infliximab treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced a new method for detecting antibody levels in individual patients treated with infliximab, a biologic therapy that has been used to treat more than a million patients across a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease and ulcerative colitis.

14 May 2010

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Soligenix, Inc., a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids." The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract.

10 May 2010

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Osiris Therapeutics, Inc., the leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and orthopedic areas, announced today its results for the first quarter of fiscal 2010.

7 May 2010

$Inflammatory bowel disorders can raise risk of osteoporotic fractures$

Inflammatory bowel disorders can raise risk of osteoporotic fractures

A team of scientists from the University Hospitals of Geneva and Lausanne have shown that young people with inflammatory bowel diseases have low bone mass and poor bone architecture compared to healthy people of the same age, placing them at increased risk of fracture.

7 May 2010

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced the presentation of data on its novel resolvins for the treatment of both ocular surface diseases and retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida, being held May 2-6, 2010.

7 May 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Osiris Therapeutics Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

6 May 2010

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

First clinical trial results of XOMA 052 in patients with uveitis of Behcet's disease presented at EULAR 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Cognitive-behavioral, skills-based treatment intervention program shows promise for teenagers with IBD

Positive initial results from Nektar Therapeutics' NKTR-102 Phase 2 study for metastatic breast cancer

Update on Phase II clinical study of CH-4051 in rheumatoid arthritis

Boosting levels of ABCG1 protein in diabetics will improve insulin production

Phase 2 Study: NKTR-102 holds great therapeutic potential for women with platinum-resistant/refractory ovarian cancer

La Jolla Institute scientist finds protein key to insulin secretion

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

ACG announces release of new IBD podcast series

Nektar Therapeutics to present data of NKTR-102 Phase 2 clinical trial in ovarian cancer at 46th ASCO

Narrow-band imaging could be novel tool for in vivo assessment of mucosal angiogenesis

USPTO issues Soligenix patent for use of beclomethasone dipropionate in treatment of IBS

SQI announces poster presentations on novel diagnostic assays at 7th International Congress on Autoimmunity

Prometheus announces novel method for early detection of HACA during infliximab treatment

European patent strengthens Soligenix' topically active steroid intellectual property portfolio

Osiris Therapeutics reports net income of $2.4M for first-quarter 2010

Inflammatory bowel disorders can raise risk of osteoporotic fractures

Resolvyx presents new data on RX-10001 for corneal herpes simplex virus infection at ARVO 2010

OSIR reports net income of $15.7M for fourth-quarter 2009 compared to net loss of $7.8M in 2008: MicroStockProfit.com

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in